Synagis should be administered in a dose of 15 mg per kg intramuscularly using aseptic technique, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve.
Older infants and children with risk factors including heart and lung disease, congenital heart disease, asthma and cystic fibrosis might receive different vaccines later during the first year of life. This group would begin vaccinations between 2 and 6 months of age.
The development of respiratory syncytial virus (RSV) vaccines has been identified as a priority for the WHO Initiative for Vaccine Research. However, as of October 6, 2021, the U.S. CDC says there are no Approved RSV vaccines in the USA.
Synagis is a prescription medicine used as a prophylaxis for Respiratory Syncytial Virus (RSV) in children. Synagis may be used alone or with other medications. Synagis belongs to a class of drugs called RSV Agents.
Upon reconstitution, Synagis® (palivizumab) contains the following excipients: 47 mM histidine, 3.0 mM glycine and 5.6% mannitol and the active ingredient, palivizumab, at a concentration of 100 milligrams per mL solution. The reconstituted solution should appear clear or slightly opalescent.
Synagis is given by injection (shot) into the leg muscle once a month for up to 5 months starting in November through March. It is usually given at the doctor's office or at home by a nurse.
Synagis is administered in your home by an OSF Home Care Services nurse. The nurse will administer a Synagis injection into your child's thigh. Synagis injections will be given monthly beginning in October and running through the end of the RSV season into the Spring. It is important not to miss any injections.
Synagis is used to prevent serious lung disease caused by respiratory syncytial virus in premature infants, and infants born with certain lung disorders or heart disease. Synagis works best in children who are 24 months old or younger at the beginning of RSV season (6 months or younger for premature infants).
Just one preventative RSV shot, called Synagis, has been approved. The monthly vaccine from Swedish Orphan Biovitrum can be used in high-risk infants.
There is no vaccine yet to prevent RSV infection, but scientists are working hard to develop one. And there is a medicine that can help protect some babies at high risk for severe RSV disease.
Palivizumab is an RSV-specific monoclonal antibody licensed for the prevention of serious lower respiratory tract infection (LRTI) caused by RSV in high-risk children. Several prospective clinical trials have demonstrated an efficacy of 45%–82% against RSV-related hospitalizations in high-risk infants.
No vaccine is currently approved for respiratory syncytial virus, or RSV. However, for the first time in decades, numerous vaccines are in the pipeline — particulary in the past 5 years. The increase in activity followed a long delay after a catastrophic vaccine failure in the 1960s killed two infants.
SYNAGIS is supplied in single-dose vials containing either 50 mg or 100 mg of product, and is administered by intramuscular injection. Vials used for single dose only are currently available in a liquid solution. SYNAGIS is supplied as a single-dose vial and does not contain preservatives.
Immunity after RSV infection does occur, but is not lifelong. Repeat infections are known to occur, although they may be milder. The duration is unknown.
Intramuscular Solution
| Quantity | Per unit | Price |
|---|
| 0.5 milliliters | $3,418.86 | $1,709.43 |
| 1 milliliter | $3,219.43 | $3,219.43 |
Administration:
- Palivizumab is given as an IM injection into the vastus lateralis muscle in the anterolateral thigh.
- If the dose is greater than 1 ml the volume to be injected should be given as a divided dose.
SYNAGIS is the first and only FDA-approved monoclonal antibody for the prevention of severe RSV disease.
Respiratory Syncytial Virus (RSV) Infection. Related Pages. Respiratory syncytial (sin-SISH-uhl) virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults.
SIDE EFFECTS: Fever, cough, earache, runny nose, or pain/redness/swelling at the injection site may occur. If any of these effects persist or worsen, contact the doctor or pharmacist promptly.
